Indication of the Parent Protocol research hub

Remibrutinib Open Label Roll-over Post-trial Access Protocol

This study is for people already taking remibrutinib in a Novartis trial who are benefiting from it. It allows them to keep taking the medicine to see its long-term effects, especially if they can't get it otherwise.